The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

por Pennock, Gregory K., Chow, Laura Q.M.
Publicado en Oncologist (2015)

Phase 1 trial of ALT-801, an interleukin-2/T cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies

por Fishman, Mayer N., Thompson, John A., Pennock, Gregory K., Gonzalez, Rene, Diez, Luz M., Daud, Adil I., Weber, Jeffery S., Huang, Bee Y., Tang, Shamay, Rhode, Peter R., Wong, Hing C.
Publicado 2011

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

por Apolo, Andrea B, Ellerton, John A, Infante, Jeffrey R, Agrawal, Manish, Gordon, Michael S, Aljumaily, Raid, Gourdin, Theodore, Dirix, Luc, Lee, Keun-Wook, Taylor, Matthew H, Schöffski, Patrick, Wang, Ding, Ravaud, Alain, Manitz, Juliane, Pennock, Gregory, Ruisi, Mary, Gulley, James L, Patel, Manish R
Publicado en J Immunother Cancer (2020)

Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

por Tap, William D., Jones, Robin L., Van Tine, Brian A., Chmielowski, Bartosz, Elias, Anthony D., Adkins, Douglas, Agulnik, Mark, Cooney, Matthew M., Livingston, Michael B., Pennock, Gregory, Hameed, Meera R., Shah, Gaurav D., Qin, Amy, Shahir, Ashwin, Cronier, Damien M., Ilaria, Robert, Conti, Ilaria, Cosaert, Jan, Schwartz, Gary K.
Publicado en Lancet (2016)